Vaxdyn Closes €11M Series A to Advance Vaccines Against Antimicrobial-Resistant Bacteria

Vaxdyn Raises €11 Million Series A Led by Biovance Capital

Seville-based biotech Vaxdyn has secured €11,000,000 in a Series A round. The funding was announced on September 7, 2026. Biovance Capital led the round, with participation from Arcano Partners' Asset Management division and the European Innovation Council (EIC) Fund.

What Vaxdyn Does

Vaxdyn develops preventive vaccines against antimicrobial-resistant Gram-negative bacteria. Its targets include Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and pathogenic Escherichia coli—pathogens ranked among the most critical threats by the WHO. The company is building on a proprietary vaccine platform and advancing a multi-pathogen pipeline.

Lead Candidate: K-VAX

Vaxdyn's lead candidate, K-VAX, is being prepared for a first-in-human Phase 1 trial against K. pneumoniae and A. baumannii. This represents a significant step toward addressing hospital-acquired infections caused by these resistant pathogens.

Funding Details

• Round type: Series A
• Amount: €11,000,000
• Announced date: September 7, 2026
• Lead investor: Biovance Capital
• Participating investors: Arcano Partners' Asset Management division, European Innovation Council (EIC) Fund

Recognition and Support

Vaxdyn was the first Spanish biotech funded by CARB-X, the global public-private partnership for early-stage antibacterial development. This backing underscores the company's scientific credibility and its alignment with global efforts to combat antimicrobial resistance.

Why This Matters for the Biotech Sector

Antimicrobial resistance is a growing global health crisis, and Gram-negative bacteria are particularly challenging due to limited treatment options. Vaccines offer a preventive approach that could reduce the burden of these infections. Vaxdyn's multi-pathogen pipeline and proprietary platform position it as a notable player in the antibacterial vaccine space.

Acquisition Angle

For pharmaceutical companies with an interest in infectious diseases or vaccines, Vaxdyn represents a strategic opportunity. Its pipeline targets WHO-critical pathogens, and the lead candidate is nearing clinical-stage development. The involvement of the EIC Fund and CARB-X also signals validation from public-private partnerships focused on antibacterial innovation. An acquisition could provide a larger pharma with access to a differentiated vaccine platform and a pipeline addressing high-priority resistant infections.

Outlook

With this Series A funding, Vaxdyn is poised to advance K-VAX into Phase 1 trials and continue developing its broader pipeline. The company's progress will be closely watched as it works to bring preventive vaccines for antimicrobial-resistant Gram-negative bacteria to the clinic.